Form 4: Cardlytics CFO Granted 1 Million RSUs

Cardlytics, Inc. Chief Financial Officer David Thomas Evans was granted 1,000,000 Restricted Stock Units under a Rule 10b5-1(c) plan.

Summary

• Chief Financial Officer David Thomas Evans of Cardlytics, Inc. (CDLX) was granted 1,000,000 Restricted Stock Units (RSUs).
• The transaction occurred on January 12, 2026, with a deemed price of $0 per RSU.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock each.
• The grant was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.
• Following this transaction, the CFO beneficially owns 1,000,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of a significant number of RSUs to the CFO is generally positive as it aligns executive incentives with shareholder value and aids in retention. It's a routine compensation event, not indicative of immediate operational changes, but reflects confidence in long-term executive commitment.

Positives

• The grant of 1,000,000 Restricted Stock Units to the CFO aligns management's interests with long-term shareholder value.
• The Rule 10b5-1(c) plan indicates a structured and pre-arranged approach to executive equity compensation.

Risks

• Vesting of the RSUs is contingent upon the Reporting Person remaining employed by the Issuer on the specified vesting dates.

Future Outlook

The vesting schedule for the RSUs extends through February 1, 2028, indicating a long-term incentive structure for the CFO, contingent on continued employment.

Industry Context

Equity grants, particularly Restricted Stock Units, are a common form of executive compensation in the technology and growth sectors to attract, retain, and incentivize key personnel, aligning their interests with long-term company performance. This practice is prevalent in competitive markets like digital advertising and fintech, where Cardlytics operates.

Comparison to Industry Standards

• The grant of 1,000,000 RSUs to a CFO is a significant equity award, common for executives in growth-oriented tech companies like Cardlytics, which operates in the digital advertising and fintech space.
• Companies such as PayPal, Block (Square), and other ad-tech firms frequently use substantial RSU grants to retain top talent, especially in competitive markets.
• The multi-year vesting schedule (through February 2028) is standard practice to ensure long-term commitment and performance alignment, similar to compensation structures seen at companies like Meta or Google for their senior executives.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's interests with long-term company performance and shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives within the company.

Next Steps

• The RSUs will vest according to the specified schedule, with the first vesting on February 1, 2027, and subsequent quarterly vesting through February 1, 2028, contingent on continued employment.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to the Chief Financial Officer. While it aligns executive incentives with long-term shareholder value, it does not present new information that would fundamentally alter the investment thesis for Cardlytics. It's a standard operational event, not a catalyst for a 'buy' or 'sell' recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Cardlytics, CDLX, Restricted Stock Units, RSU, CFO, Equity Compensation, Form 4, Insider Transaction, Executive Compensation, Stock Grant